Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 517-521

  Nobile, Maria Teresa ^a   Barzacch, Maria Cristina ^a   Sanguineti, Ornella ^a   Chiara, Silvana ^a   Gozza, Alberto ^a   Vincenti, Maura ^a   Lavarello, Andrea ^b   Cognein, Paola ^a   Lionetto, Rita ^a   Percivale, Pier Luigi ^a   Bertoglio, Sergio ^a   Murolo, Carmelina ^a   Esposito, Mauro ^a   Vannozzi, M Ornella ^a   Rosso, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale di Sestri Levante   (Italy)

Author keywords

Advanced colorectal cancer; High dose 5 FU plus L LV; Short term infusion

Indexed keywords

FLUOROURACIL; FOLIC ACID DERIVATIVE; FOLINIC ACID; PYRIMIDINE ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; EPISTAXIS; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 15144357461     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxynosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3283-3295,1981.
2. Houghton JA, Williams LG, de Graaf SSN: Relationship between dose rate of (6RS) leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylene-tetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50: 3493-3502, 1990.
3. Ardalan B, Glazer R: An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 8: 157-167, 1991.
4. Rustum YM, Trave F, Zakrzewski SF et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5-165-170, 1987.
5. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
6. Benz C, Tillis T, Tattelman E, Cadman E: Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42: 2081-2088, 1982.
7. Marsh JC, Bertino JR, Katz KH et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9: 371-380, 1991.
8. Advanced Colorectal Cancer Meta-Analysis Project. Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960-969, 1994.
9. Kemeny N, Younes A: Alfa 2A Interferon and 5-Fluorouracil for advanced colorectal carcinoma: The Memorial Sloan-Kettering Experience. Sem Oncol 19 (2) Suppl 3: 171-175, 1992.
10. Ardalan B, Chua L, Tian R et al: A Phase II study of weekly infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
11. Diaz-Rubio E, Aranda E, Camps C, Fernandez-Martos C et al: A phase II study of weekly 48 hours infusion with high-dose fluouracil in advanced colorectal cancer: an alternative to biochemical modulation. J Infus Chemother 4,1: 58-61, 1994.
12. Miller AB, Hoogstraten B, Staquet M el at. Reporting results of cancer treatment. Cancer 47: 207-14, 1981.
13. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 457-481, 1958.
14. Houghton JA, Maroda SJ, Philips JO, Houghton PJ: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res 41: 144-149, 1981,
15. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986; 46: 5229-5235, 1986.
16. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989.
17. Diaz-Rubio E, Aranda E, Martin M, Gonzalez Mancha R, Gonzalez Larriba JL: Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 26: 727-729, 1990.
18. Aranda E, Cervantes A, Dorta J et al: A phase II trial of weekly high dose continuous infusion 5-Fluorouracil plus oral Leucovorin in patients with advanced colorectal cancer. Cancer 76: 559-563, 1995.
19. Straw JA, Szapary D, Wynn WT: Pharmacokinetics of the diasteroisomers of leucovorin after intravenous and oral administration. Cancer Res 44: 3114-3119, 1984.
20. Schleyer E, Reinhardt J, Grimm M et al: Pharmacokinetics and protein binding of leucovorin diastereomers. Proc Am Assoc Cancer Res 33: 532 (Abstr 3183), 1992.
21. Vannozzi MO, Nobile MT, Sanguineti O et al: Pharmacokinetics of (6S)Leucovorin and 5-Methyltetrahydrofolate after 4-hour continuous intravenous infusion followed by repeated oral doses of (6S)-Leucovorin in patients with colorectal cancer trated with 5-fluorouracil. Clin. Drug Invest 12(1): 39-45, 1996.
22. Weh HJ, Wilke HJ, Dierlamm J et al: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5: 233-237, 1994.